|
- Rouzade ML, Fioramonti J, Bueno L. A model for evaluation of gastric sensitivity in awake rats. Neurogastroenterol Motil 1998;10:157–163.
- Mori T, Kawano K, Shishikura T. 5-HT3-receptor antagonist inhibits visceral pain differently in chemical and mechanical stimuli in rats. J Pharmacol Sci 2004;94:73–76.
- Louvel D, Delvaux M, Staumont G, et al. Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome? Gastroenterology 1996;110:351–361.
- Bouin M, Delvaux M, Blanc C, et al. Intrarectal injection of glycerol induces hypersensitivity to rectal distension in healthy subjects without modifying rectal compliance. Eur J Gastroenterol Hepatol 2001;13:573–580.
- Morteau O, Hachet T, Caussette M, et al. Experimental colitis alters visceromotor response to colorectal distension in awake rats. Dig Dis Sci 1994;39:1239–1248.
- Al Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000;119:1276–1285.
- Gue M, Rio-Lacheze C, Eutamene H, et al. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 1997;9:271–279.
- Coelho AM, Fioramonti J, Bueno L. Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve. Am J Physiol 2000;279:G781–G790.
- Barreau F, Cartier C, Ferrier L, et al. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats. Gastroenterology 2004;127:524–534.
- Woodsworth RS, Sherrington CS. A pseudo affective reflex and its spinal path. J Physiol 1904;31:234–243.
- Kamp EH, Jones RC, III, Tillman SR, et al. Quantitative assessment and characterization of visceral nociception and hyperalgesia in mice. Am J Physiol 2003;284:G434–G444.
- Ozaki N, Bielefeldt K, Sengupta JN, et al. Models of gastric hyperalgesia in the rat. Am J Physiol 2002;283:G666–G676.
- Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudo affective reflexes in the rat. Brain Res 1988;450:153–169.
- Su X, Julia V, Gebhart GF. Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J Neurophysiol 2000;83:963–970.
- Booth CE, Kirkup AJ, Hicks GA, et al. Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology 2001;121:358–369.
- Fioramonti J, Gaultier E, Toulouse M, et al. Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 2003;15:363–369.
- Johnson AC, Myers B, Lazovic J, et al. Brain activation in response to visceral stimulation in rats with amygdala implants of corticosterone: an FMRI study. PLoS One 2010 Jan 5;5(1):e8573.
- McLean PG, Picard C, Garcia-Villar R, et al. Effects of nematode infection on sensitivity to intestinal distension: role of tachykinin NK2 receptors. Eur J Pharmacol 1997;337:279–282.
- Gue M, Junien JL, Bueno L. The kappa agonist fedotozine modulates colonic distention-induced inhibition of gastric motility and emptying in dogs. Gastroenterology 1994;107:1327–1334.
- Tjeerdsma HC, Smout AJ, Akkermans LM. Voluntary suppression of defecation delays gastric emptying. Dig Dis Sci 1993;38:832–836.
- Lee KJ, Tack J. Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil 2010;16:251–257.
- Gue M, Peeters T, Depoortere I, et al. Stress-induced changes in gastric emptying, postprandial motility, and plasma gut hormone levels in dogs. Gastroenterology 1989;97:1101–1107.
- Al-Qarawi AA, Ali BH, Al-Mougy SA, et al. Gastrointestinal transit in mice treated with various extracts of date (Phoenix dactylifera L.). Food Chem Toxicol 2003;41:37–39.
- Broccardo M, Improta G, Tabacco A. Central effect of SNC 80, a selective and systemically active delta-opioid receptor agonist, on gastrointestinal propulsion in the mouse. Eur J Pharmacol 1998;342:247–251.
- Williams CL, Peterson JM, Villar RG, et al. Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol 1987;253:G582–G586.
- Kadowaki M, Wade PR, Gershon MD. Participation of 5-HT3, 5-HT4, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon. Am J Physiol 1996;271:G849–G857.
- Cann PA, Read NW, Holdsworth CO. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984;25:168–173.
- Cann PA, Read NW, Holdsworth CD, et al. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984;29:239–247.
- Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79–86.
- Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–1666.
- Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877–1888.
- Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671–676.
- Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347–1356.
- Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354–360.
- Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761–768.
- Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702–1712.
- Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714–1724.
- von der Ohe MR, Camilleri M, Kvols LK, et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993;329:1073–1078.
- Plourde V, Lembo T, Shui Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in human. Am J Physiol 1993;265:G742–G751.
- Hasler WL, Soudah HC, Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 1993;104:1390–1397.
- Hasler W, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994;268:1206–1211.
- Bradette M, Delvaux M, Staumont G, et al. Octreotide increa